Premium Nahrungsergänzungsmittel | artgerecht

LADA: Latent Autoimmune Diabetes in Adults Explained

Latent Autoimmune Diabetes in Adults (LADA) is a slow-progressing autoimmune form of diabetes that begins in adulthood. It is frequently misdiagnosed as type 2 diabetes in its early stages.

Regular tips about health Regular tips about health

Things worth knowing about "Latent Autoimmune Diabetes in Adults"

Latent Autoimmune Diabetes in Adults (LADA) is a slow-progressing autoimmune form of diabetes that begins in adulthood. It is frequently misdiagnosed as type 2 diabetes in its early stages.

What is Latent Autoimmune Diabetes in Adults?

Latent Autoimmune Diabetes in Adults, commonly known as LADA, is a form of diabetes mellitus in which the immune system gradually attacks and destroys the insulin-producing beta cells of the pancreas. Unlike classic type 1 diabetes, this autoimmune process in LADA progresses slowly over months or even years. Because it typically begins in adulthood and does not initially require insulin therapy, it is frequently misclassified as type 2 diabetes. For this reason, LADA is sometimes referred to as type 1.5 diabetes.

Causes

Like type 1 diabetes, LADA is driven by an autoimmune reaction. The immune system produces antibodies that target structures within the pancreas, most notably:

GAD antibodies (glutamic acid decarboxylase antibodies) – the most commonly detected marker
IA-2 antibodies (islet antigen-2 antibodies)
Insulin autoantibodies (IAA)
ZnT8 antibodies (zinc transporter 8 antibodies)

The precise triggers for this autoimmune response are not yet fully understood. A combination of genetic predisposition and environmental factors – such as viral infections – is believed to play a role.

Symptoms

In its early stages, LADA often resembles type 2 diabetes and may present with non-specific symptoms, including:

Elevated blood glucose levels
Increased thirst and frequent urination
Fatigue and reduced performance
Weight loss (often less pronounced than in type 1 diabetes)
Blurred vision

A key clinical indicator of LADA is that blood glucose control, initially managed with oral antidiabetic medications, gradually deteriorates over time, eventually requiring insulin therapy. This progressive loss of beta cell function distinguishes LADA from typical type 2 diabetes.

Diagnosis

Diagnosing LADA can be challenging because it closely resembles type 2 diabetes clinically. The following diagnostic criteria are typically applied:

Adult age at diagnosis (usually over 30 years of age)
Presence of diabetes-related autoantibodies in the blood (particularly GAD antibodies)
Initial insulin independence for at least 6 months after diagnosis

In addition, measuring the C-peptide level – which reflects the remaining insulin-secreting capacity of the pancreas – is helpful. In LADA, C-peptide levels decline progressively as the disease advances.

Treatment

Since LADA involves ongoing autoimmune destruction of beta cells, treatment focuses on preserving residual insulin production as long as possible while maintaining good blood glucose control.

Early Insulin Therapy

Many experts advocate for early initiation of insulin therapy, as it can reduce the workload on the remaining beta cells and help preserve their function longer. Early insulin use may also slow down the autoimmune process.

Oral Antidiabetic Medications

In the early stages, oral antidiabetic drugs may be used. However, sulfonylureas are generally avoided, as they may overstimulate already compromised beta cells and accelerate their loss.

Lifestyle Modifications

As with all forms of diabetes, a healthy diet, regular physical activity, and maintaining a healthy body weight are essential supportive measures to improve insulin sensitivity and overall metabolic health.

Regular Monitoring

Ongoing monitoring of blood glucose levels, HbA1c (long-term blood glucose marker), C-peptide levels, and autoantibody titers is essential for adapting the treatment plan over time and anticipating the need for insulin therapy.

References

Fourlanos S, Dotta F, Greenbaum CJ et al. - Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48(11):2206-2212. (PubMed)
Buzzetti R, Tuomi T, Mauricio D et al. - Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Diabetes. 2020;69(10):2037-2047. (PubMed)
American Diabetes Association - Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.